Brokers Set Expectations for TARA Q2 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Stock analysts at HC Wainwright issued their Q2 2026 EPS estimates for shares of Protara Therapeutics in a research report issued on Monday, November 24th. HC Wainwright analyst A. Maldonado expects that the company will post earnings of ($0.34) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $23.00 price objective on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share. HC Wainwright also issued estimates for Protara Therapeutics’ Q3 2026 earnings at ($0.35) EPS and Q4 2026 earnings at ($0.36) EPS.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.60.

Protara Therapeutics Trading Up 2.6%

NASDAQ:TARA opened at $7.56 on Tuesday. Protara Therapeutics has a 1-year low of $2.48 and a 1-year high of $10.48. The firm has a market capitalization of $291.72 million, a price-to-earnings ratio of -4.67 and a beta of 1.59. The business’s 50-day moving average price is $5.07 and its two-hundred day moving average price is $3.82.

Protara Therapeutics (NASDAQ:TARA) last announced its quarterly earnings data on Monday, November 10th. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.08.

Institutional Investors Weigh In On Protara Therapeutics

Several large investors have recently modified their holdings of TARA. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Protara Therapeutics during the second quarter worth about $30,000. Quadrature Capital Ltd bought a new stake in Protara Therapeutics during the 2nd quarter worth approximately $35,000. Almanack Investment Partners LLC. acquired a new stake in Protara Therapeutics during the 3rd quarter worth approximately $59,000. Charles Schwab Investment Management Inc. bought a new position in Protara Therapeutics in the first quarter valued at approximately $64,000. Finally, JPMorgan Chase & Co. acquired a new position in shares of Protara Therapeutics in the second quarter valued at approximately $46,000. 38.13% of the stock is currently owned by institutional investors.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.